Papillary Renal Cell Carcinoma — Trials

Papillary Renal Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

32 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 14
Recruiting: 5
Ph III recruiting: 0
Growth YoY: —
Industry share: 21%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05043090	Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC(SAMETA)	active not recruiting	Phase 3	148	AstraZenecaINDUSTRY	25	May 22, 2026	clinicaltrials
NCT06146777	Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy	not yet recruiting	Phase 3	468	First Affiliated Hospital, Sun Yat-Sen UniversityOTHER	0